Latest Breaking News On - Stuart rich - Page 6 : comparemela.com

25 Tenax Therapeutics, Inc. (NASDAQ: TENX)announced positive data from its Phase 2 HELP Study that evaluated levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.  Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Placebo-Controlled HELP Trial was published in the Journal of American College of Cardiology: Heart Failure. The publication had a 84% responder rate during the open label phase as 37 or 44 patients met responder criteria and were randomized to levosimendan (n=18) or placebo (n=19).  Levosimendan did not significantly reduce the primary endpoint of exercise-PCWP but has reduced PCWP measured across all exercise stages.  The 6 week study design utilized invasive cardiovascular hemodynamics and secondary clinical endpoints that include a 6 minute walk test.

Daniel burkhoffCirculatory support research at cardiovascular foundationJournal of american college cardiologyTenax therapeutics incTenax therapeuticsLevosimendan improves hemodynamicsExercise toleranceAmerican collegeHeart failureMechanical circulatory support researchCardiovascular research foundationStuart richChief medical officerPrincipal investigatorஇதழ் ஆஃப் அமெரிக்கன் கல்லூரி இருதயவியல்உடற்பயிற்சி சகிப்புத்தன்மை